Dental implant procedures contribution to the total antibiotic use in Swedish dentistry. A register-based study.

OBJECTIVE: To study the influence of demographic and organizational factors to antibiotic utilization in dental implant surgery in Sweden. MATERIAL AND METHODS: Descriptive statistics regarding antibiotic prescription between 2009 and 2019 was retrieved from two national registers, the Swedish Prescribed Drug Register and the Dental Health register, both administered by the National Board of Health and Welfare. RESULTS: During the years 2009-2019 a significant decrease of the proportion of prescriptions of systemic antibiotics in conjunction with implant surgical procedures occurred in all patient groups where the most common procedure was the insertion of a single implant. The proportion of dental visits when implant surgical treatment was performed which resulted in a prescription of antibiotics decreased significantly from 1/3 to approximately 1/5. However, comparing Public and Private dental care providers, the reduction was significantly greater in Public dental care. Patients with low level of education in urban regions, treated in Private dental clinics were more likely to receive antibiotics in conjunction to implant surgery compared to other groups. Phenoxymethylpenicillin is the most widely used substance in conjunction with implant surgery. CONCLUSION: There is still room for improvement in reduction of antibiotic prescriptions in conjunction to implant surgical procedures in Sweden.

Effect of governmental strategies on antibiotic prescription in dentistry.

Objective: To study the effect of governmental strategies, to constitute and publish recommendations on antibiotic usage in dentistry, on the antibiotic consumption.Material and methods: Descriptive statistics regarding antibiotic prescription between 2009 and 2017 was retrieved from two national registers, the Swedish Prescribed Drug Register and the Dental Health register, both administered by the National Board of Health and Welfare. Age standardization was applied to alleviate the comparison between gender, different regions and years.Results: The number of dispatched prescriptions of antibiotics from dentists was reduced with 31% during the study period. 10% of the visits to a dentist generated an antibiotic prescription corresponding to 7% of the total number of antibiotic prescriptions. A decline in prescription was observed after publication of national recommendations for antibiotics prophylaxis in 2012 and antibiotic treatment in 2014. Unexplained geographical and gender differences in the rates of prescription were seen.Conclusions: Data indicates a correlation between introduction of governmental strategies to reduce antibiotic usage and declining antibiotic prescription. Although a marked reduction in prescription was observed, the results indicate that there is further potential for improvement of antibiotic stewardship in odontology.

The Swedish dental health register - validation study of remaining and intact teeth.

BACKGROUND: Sweden has a long tradition of nationwide registers enabling population-based research of high quality and validity. We aimed to describe the content and validity of reported number of remaining and intact teeth in the Swedish Dental Health Register and report some descriptive data on dental health care utilization. METHODS: The Swedish Dental Health Register was initiated in July 1st 2008 and contains individual data on dental health care to the whole adult population of Sweden. The dental care given freely to children and young adults is not included. Descriptive data on remaining, intact teeth and dental health care utilization is presented by proportion of the population stratified by sex and age. We conducted a validation study, by manual review of randomly sampled 1500 dental health visits records, to assess reported number of teeth to the register with what was actually recorded in the dental health care record (gold standard), analyzed by positive predictive value (PPV) and Bland-Altman plots. RESULTS: Of the Swedish adult population 2014, 2.6 million (69%) men and 2.9 million (76%) women had at least one visit to a dentist during a two-year period 2013 to 2014. More than half of the population up to age 64 have all remaining teeth (28 teeth or more). Of the 1500 requested dental records 1131 (75%) were received. The positive predictive value for patients reported to the register as having at least 1 tooth up to 31 intact teeth was 91.5% (95% confidence interval 89.0-93.5, 567 manually reviewed to be correct out of 620 reported). CONCLUSIONS: For patients coded as having less than 32 intact teeth but not being edentulous the reported number of remaining and intact teeth is to a very high degree correct. However, the correctness for those coded as edentulous or having 32 remaining intact teeth is low and varies substantially by age.

Caries treatment in Swedish adults: effectiveness, costs and equity. A 4-year follow-up study of data from the Swedish national dental health register.

At a national level, planning and management of dental services should be based on assess- ments of equity, effectiveness and costs. In Sweden, data for the adult population are now acces- sible through The Swedish dental health register, at The National Board of Health and Welfare. This study, on two large cohorts of Swedish adults, is based on longitudinal follow-up data, retrieved from the Swedish dental health register.The aims were twofold: to assess frequencies and costs of fillings and crowns, including subsequent repair; secondly to study the relationship between preventive and restorative dental treatment.The Swedish dental health register pro- vides data on the adult population which offers a new perspective on public health aspects of management of dental care at the national level. A longitudinal, prospective study model was used to follow-up two large cohorts for over four years. In the first cohort, data on 1,088,923 adult patients were analysed with reference to provision of single crowns and fillings over a period of 42 -48 months.The second cohort comprised 1,703,147 adult patients: the data were analysed with reference to preventive interventions over a period of 48 - 54 months. Frequencies of distribution of dental care by age group showed that the cohorts were representative for the whole patient group.With respect to equity, the average number of dentist appointments per i,ooo inhabitants for all 21 regions of Sweden was 140 to 160, despite major variations in geographic conditions and population densities. With respect to effectiveness, about 76% of the teeth with index interven- tions required no additional intervention over four consecutive years of follow-up. For the remain- ing 24% of the teeth 77% had only one additional intervention. When differences of case-mix were taken into account, the costs of repairs to earlier ihterventions were basically similar, regardless of age-group.There were no gender differences. However, there were pronounced differences, of up to three intact teeth, among patients from different regions of Sweden. Follow-up of effects of caries prevention showed no gender differences. However, costs for reparative interventions increased with higher costs for preventive treatment. Moreover, the longer the interval between preventive interventions, the lower the costs for reparative interventions.The national dental health register is a potentially valuable source of data for dental research. In this study, longitu- dinal registry data on restorative and preventive treatment were retrieved and analysed, with reference to efficacy, costs and equity. The results have potential application in improving mana- gement of public dental health.

Stimulant use and its impact on growth in children receiving growth hormone therapy: an analysis of the KIGS International Growth Database.

BACKGROUND: Children receiving stimulants for attention deficit hyperactivity disorder (ADHD) frequently present to pediatric endocrinology clinics for evaluation and treatment of growth disorders. The worldwide prevalence of stimulant use in children with ADHD also receiving recombinant human growth hormone (rhGH) and the impact on response to rhGH are unknown. METHODS: Data on children enrolled in the KIGS® (Pfizer International Growth Study) registry were evaluated for the associated diagnosis of ADHD prior to initiation of Genotropin® rhGH. Concomitant stimulant medications and auxological information were captured. Response to rhGH was evaluated using established growth prediction models. RESULTS: The prevalence of ADHD in KIGS was 2.3% (1,748/75,251), with stimulants used in 1.8% (1,326/75,251). Children with idiopathic growth hormone deficiency (IGHD) who received stimulants grew significantly less (1.1 cm) in the first year of rhGH therapy than expected for rhGH-treated non-ADHD IGHD children. After one year of rhGH, idiopathic short stature (ISS) children with ADHD were significantly shorter [0.74 cm (with stimulants) and 0.69 cm (without stimulants)] than non-ADHD ISS children. CONCLUSIONS: We demonstrated an impaired response to rhGH in IGHD and ISS children with ADHD. Our findings suggest that the ADHD phenotype, alone or in conjunction with stimulant therapy, may impair the short-term growth response to rhGH.

Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.

CONTEXT: Pegvisomant is a GH receptor antagonist. The ACROSTUDY is a global safety surveillance study of long-term treatment of acromegaly with pegvisomant. OBJECTIVE: The objective of the study was to monitor long-term safety and treatment outcomes. DESIGN: ACROSTUDY is open to all patients with acromegaly who are treated with pegvisomant. We report an interim analysis of data captured from 1288 subjects enrolled before a database freeze of December 31, 2009. SETTING: This was a global noninterventional surveillance study. MAIN OUTCOME MEASURE(S): Long-term monitoring of safety, including central magnetic resonance imaging (MRI) reading and treatment outcomes, was measured. RESULTS: Subjects (n = 1288) were treated with pegvisomant for a mean of 3.7 yr and followed up in ACROSTUDY for a mean of 2.1 yr. A total of 1147 adverse events (AE) were recorded in 477 subjects (37%), among which 192 AE in 124 subjects (9.6%) were considered to be related to pegvisomant. Serious AE were recorded in 159 subjects (12.3%), whereas pegvisomant-related Serious AE were recorded in 26 subjects (2%). No deaths (15 subjects; 1.2%) were attributed to pegvisomant use. The incidence of increase in pituitary tumor size in the subset with confirmed MRI increases on central reading represented 3.2% of the overall cohort with at least two available MRI (n = 936). Injection-site reactions were reported in 28 cases (2.2%). In 30 patients (2.5%), an elevated aspartate aminotransferase or alanine aminotransferase of more than 3 times the upper level of normality was reported. There were no reports of liver failure. After 5 yr of pegvisomant treatment, 63.2% of subjects had normal IGF-I levels at a mean dose of 18 mg/d. CONCLUSIONS: Data entered and evaluated in ACROSTUDY indicate that pegvisomant is an effective and safe medical treatment in patients with acromegaly. The reported low incidence of pituitary tumor size increase, liver enzyme elevations, and lipodystrophy at the injection site are reassuring.

Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.

Context Pegvisomant (Somavert, Pfizer Inc.) is the first and only available GH receptor antagonist. ACROSTUDY is an international surveillance study that offers inclusion in a web-based registry to all patients with acromegaly treated with pegvisomant; it aims at monitoring long-term safety and efficacy of this compound. Patients and methods This report summarizes the main baseline characteristics of this particular population of patients. In February 2009, over 300 centres in 10 countries had contributed 792 patients. A gradual increase in cumulative patient recruitment was observed since the launching of ACROSTUDY in 2004: from 116 patients in 2005, it steeply increased to 792 at the latest data freeze in February 2009. At the time of enrolment, 91.8% of patients were already treated with pegvisomant but baseline was considered at the time of pegvisomant start. IGF1 concentrations were measured at local laboratories. Results Of all patients, 80% were reported to have had surgery and 33% to have received radiation therapy. Of the 792 patients, 14% had received no prior medical treatment before pegvisomant start, 65.9% had received somatostatin analogues and 18.6% dopamine agonists. Interestingly, 66.7% had received only pegvisomant at study start, while it was taken in association with dopamine agonists in 5.7%, with somatostatin analogues in 23.4% and with both types of agents in 3.8%. Mean IGF1 at baseline was 522 ng/ml. Conclusion Analysis of the baseline features of these patients treated with pegvisomant and reported in the ACROSTUDY database underscores the severity of the disease in this subset of the population of patients with acromegaly previously unresponsive to several medical, surgical or radiation treatment approaches.

Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age.

BACKGROUND AND METHODS: We assessed the value of in- sulin-like growth factor I (IGF-I) monitoring during growth hormone (GH) treatment by retrospectively examining the relationships between (1) GH dose and IGF-I response, (2) baseline serum IGF-I concentration and growth response and (3) serum IGF-I response and growth response after 1 year of GH treatment among patients in the Pfizer International Growth Study database (KIGS). KIGS patients were eligible for the study if they were classified as having idiopathic GH deficiency, acquired GH deficiency, Turner syndrome or were born small for gestational age. RESULTS: Correlations between GH dose and IGF-I response and between pretreatment IGF-I values and first-year growth response were weak across all groups. Correlations between the IGF-I response and growth response after 1 year of treatment were greater than those between baseline serum IGF-I values and first-year growth response. Pre- and posttreatment clinical characteristics were consistently different across all groups, but the numerous technical factors affecting these relationships are remediable. CONCLUSIONS: IGF-I monitoring during GH therapy is a valuable tool to monitor compliance and ensure that IGF-I levels do not exceed the normal range for extended periods. IGF-I monitoring may help clinicians increase GH doses as needed during puberty to achieve normal serum IGF-I values and normal or enhanced growth.